Phase II Long Term, Randomized Study of Recombinant Human Insulin-like Growth Factor I in Children With Hyperinsulinism

Effect of Novel Glucagon Receptor Antagonist REMD-477 on Glucose and Adipocyte Metabolism in T2DM

NCT05093517 ·Status: COMPLETED ·Phase: EARLY_PHASE1

Metformin to Treat Obesity in Children With Insulin Resistance

NCT00005669 ·Status: COMPLETED ·Phase: PHASE2

Safety and Efficacy of Insulin Degludec/Insulin Aspart in Patients With T1DM

NCT04965051 ·Status: UNKNOWN ·Phase: NA

Glucagon Counterregulation in Type 1 Diabetes

NCT03547427 ·Status: TERMINATED ·Phase: NA

Modulation of Human Myocardial Metabolism by GLP-1 Dose Response

NCT01607450 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

A Single-Dose Open-Label Study of XOMA 358 in Subjects With Congenital Hyperinsulinism

NCT02604485 ·Status: COMPLETED ·Phase: PHASE2

GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance

NCT04731272 ·Status: RECRUITING ·Phase: PHASE2

18F-L-Fluoro-DOPA PET/CT Scan Localization of Focal Pancreatic Lesions in Subjects With Hyperinsulinemic Hypoglycemia

NCT01916148 ·Status: AVAILABLE

The Effect of Byetta and Symlin on Post-meal Meal Blood Sugar Levels in Children With Type 2 Diabetes

NCT00950677 ·Status: COMPLETED ·Phase: PHASE4

Effect of 48 Hours of Treatment With the Natural Peptide-Hormone GLP-1 in Patients With Chronic Heart Failure

NCT00264199 ·Status: COMPLETED ·Phase: NA

Evaluation of Kisspeptin Stimulated Insulin Secretion With Hyperglycemic Clamp

NCT05456854 ·Status: WITHDRAWN ·Phase: PHASE1

Dipeptidyl Peptidase-4 Inhibition on Glucagon-like Peptide-1 (GLP-1)

NCT00947011 ·Status: TERMINATED ·Phase: PHASE2

Effects of Glucagon-Like Peptide-1 Analogs on Sexuality

NCT04687514 ·Status: COMPLETED ·Phase: PHASE2

A Study of Insulin Peglispro and Glargine on Fats in Participants With Type 1 Diabetes

NCT01771250 ·Status: COMPLETED ·Phase: PHASE1

The Effect of GIP and GLP-1 on Insulin and Glucagon Secretion in Patients With HNF1A-diabetes Treated With or Without Sulphonylurea

NCT03081676 ·Status: COMPLETED ·Phase: NA

Low-dose Dasiglucagon for Prevention of Insulin-Induced Hypoglycemia in People With Type 1 Diabetes

NCT04449692 ·Status: COMPLETED ·Phase: PHASE2

GLP-1 Therapy for Weight Loss and Improved Glucose Tolerance in Obese Children

NCT00886626 ·Status: COMPLETED ·Phase: PHASE2

Role of Growth Hormone Antagonism in Modulating Insulin Sensitivity in Subjects With Pre-diabetes

NCT02023918 ·Status: COMPLETED ·Phase: PHASE2

To Determine Tolerability to Glucagon Infusion in Obese Subjects

NCT02817659 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

Evaluation of the Impact of Intensive Short-Term Drug Therapy in Patients With Type 2 Diabetes Mellitus

NCT04027023 ·Status: UNKNOWN ·Phase: PHASE4

Canakinumab for the Treatment of Postprandial Hypoglycemia

NCT05401578 ·Status: RECRUITING ·Phase: PHASE3

Prevention of Postprandial Hyperglycemia by Acarbose May be a Promising Therapeutic Strategy for Reducing the Increased Risk for Cardiovascular Disease

NCT01167231 ·Status: COMPLETED

The Separate and Combined Glucagonotropic Effects of Glucose-dependent Insulinotropic Polypeptide and Alanine in Subjects With and Without Type 1 Diabetes

NCT06881472 ·Status: COMPLETED ·Phase: NA

The Role of Glucose-Dependent Insulinotropic Polypeptide in the Pathological Glucose Homeostasis Of Type 1 Diabetes

NCT03734718 ·Status: COMPLETED ·Phase: NA

A Study To Assess GW677954 Used In Combination With Insulin In Subjects Who Have Type 2 Diabetes Mellitus

NCT00437164 ·Status: TERMINATED ·Phase: PHASE2